Skip to main content
. 2005 Oct 11;93(8):896–904. doi: 10.1038/sj.bjc.6602800

Table 4. Percentage of patients experiencing toxicity by treatment arm according to WHO grades.

  5FU
5FU-LEV
5FU-FA
5FU-FA-LEV
P-value P-value
  n=269
n=310
n=268
n=296
FA effect (n=1143) LEV effect (n=1059)
Type of toxicity G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4 G1 G2 G3 G4 all grades all grades
Vomiting 15 4 0.4 17 7 0.3 0.6 17 8.6 1.9 0.4 22 8.4 1 0.3 0.004 0.11
Diarrhoea 13 5.9 2.2 12 11 3.5 10 19 9 1 12 15 8 1.7 <0.0001 0.56
Mucositis 8.9 3 0.3 0.3 9.7 5.8 0.9 16 8.2 9.7 2.2 17 13 3.7 2.7 <0.0001 0.24
Fever 0.3 0.3 1.5 0.7 0.3 1 1 0.3 0.3 0.0017 0.35
Leukopenia 8.6 6.3 0.7 0.3 9.4 6.8 0.9 9.3 5.2 1.9 0.7 8.8 5.4 0.3 1 0.92 0.77
Anemia 2.6 1.9 1.3 4.5 1.1 3.7 0.7 0.09 0.75
Thrombocytopenia 3.3 0.3 2.6 0.3 0.3 2.2 0.3 0.3 1 0.3 0.20 0.48
Skin 3.3 0.3 3.5 2.3 6.3 3.7 1.1 6.8 4.4 1 <0.0001 0.29
Congiuntivitis 0.6 1.9 1.9 3 0.7 <0.0001 0.77
Alopecia 1.5 0.3 1.3 0.6 3.4 1.1 1.1 2.4 3 0.3 0.0007 0.96
Abdominal pain 1.1 1.3 0.3 0.3 0.3 0.3 2 0.70 0.55
Anorexia 0.3 0.3 0.99
Taste alteration 0.3 0.3 0.99 0.51
Gastric ulcer 0.3 0.3 0.49 0.99
GI tract bleeding 0.3 0.3 0.3 0.87 0.26
Constipation 0.3 1 0.3 0.3 0.7 0.7 0.7 0.96 0.11
Bilirubin 1.1 0.3 0.9 0.3 0.7 0.3 1 0.3 0.96 0.99
Hypertransaminasaemia 2.2 0.3 1.6 0.3 0.3 1.1 1.4 0.3 0.22 0.75
Headhache 0.6 0.25 0.49
Fatigue 0.7 0.6 2.6 1.4 0.3 0.04 0.85
Cardiac 1.1 1.1 0.6 0.3 0.3 0.3 0.7 0.3 0.3 0.57 0.23
Neurotoxicity 0.3 0.3 0.3 0.3 1.1 0.7 0.7 0.10 0.48
Cistitis 0.3 0.3 0.3 0.3 0.7 0.99 0.95
Renal 0.3 0.6 0.3 0.7 0.99 0.97
Vascular 0.3 0.3 0.3 0.3 0.57 0.99
Allergy 0.3 0.7 0.61 0.24
Other 0.6 0.3 0.3 1.4 0.14 0.43
Toxic death 4 (1.5 %) 1 (0.3 %) 5 (1.9 %) 3 (1.0 %) 0.42 0.26